This is modestly good news for MNTA in that Teva’s US patents on the 40mg dose might have harder to overturn or circumvent than the patents on the standard 20mg dose. (MNTA is developing a generic version of Copaxone with its partner, NVS.)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.